Goldman Sachs
OREX

Goldman Sachs’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Goldman Sachs’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,720
Closed -$100K – 7693
2015
Q3 		$100K Buy
+4,720
New +$162K ﹤0.01% 6485
2014
Q3 		– Sell
-1,120
Closed -$69K – 7528
2014
Q2 		$69K Buy
+1,120
New +$65.1K ﹤0.01% 6673

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs's OREX Position: Q4 2017 in Review

Goldman Sachs sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 17,336 shares — an estimated $37K sold.

Goldman Sachs first reported a position in OREX in Q2 2013 and held it in 18 quarters. The position peaked at $4.5M in Q3 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Goldman Sachs reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 17,336 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $37K.
  • Goldman Sachs first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's Orexigen Therapeutics, Inc. position peaked at $4.5M in Q3 2014.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.